Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hydroxyprogesterone hexanoate in preparation of medicine for treating interstitial pneumonia

A hydroxyprogesterone caproate, interstitial technology is applied in the field of use of hydroxyprogesterone caproate in the preparation of a drug for treating interstitial pneumonia, and can solve the problem of lack of treatment means, glucocorticoid treatment resistance and side effects , the inability to obtain the effect of glucocorticoid therapy, etc.

Pending Publication Date: 2022-06-03
SHENZHEN EVERGREEN THERAPEUTICS CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The molecular mechanisms of glucocorticoid resistance include reduced expression of glucocorticoid receptors, defects and translocations binding to glucocorticoid receptors, genetic predisposition, activation of inflammatory signaling pathways, etc., which have been reported in 20-40% of Patients may therefore not be able to obtain effective glucocorticoid therapy
2) Side effects
[0005] In view of the current clinical lack of effective treatment for IIP, especially IFP, and the drug resistance and side effects of existing glucocorticoid therapy, there is a great need for drugs for the treatment of this disease in this field

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydroxyprogesterone hexanoate in preparation of medicine for treating interstitial pneumonia
  • Application of hydroxyprogesterone hexanoate in preparation of medicine for treating interstitial pneumonia
  • Application of hydroxyprogesterone hexanoate in preparation of medicine for treating interstitial pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Example 1 Establishment of rat model

[0151] SD rats (weight 240-280 g) were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. (animal license number: SCXK (Beijing) 2016-0006; animal certificate number: NO.110011201110788686).

[0152] The quarantine and acclimation period lasted for 1 week, after which they were divided into control group and interstitial pneumonia model group according to body weight. On day 0 of the study, rats in the model group were given a single dose of 5 mg / kg bleomycin by a single intratracheal injection of bleomycin. The rats in the control group were given a single instillation of normal saline. Immediately after completion, the animals were placed upright and rotated to facilitate even distribution of the drug in the lungs. Lie down in a warm environment and wake up naturally. Animals ate and drank freely after they were awake.

Embodiment 2

[0153] Example 2 Experimental grouping

[0154]

[0155]

Embodiment 3

[0156] Example 3 Detected indicators

[0157] General observations and inspections:

[0158] Weight, physical signs, coat status, behavioral activities, presence or absence of nervous reactions such as tremors and spasms, presence or absence of abnormal breath sounds and abnormal gait movements, response to sound shock, stool shape and color, etc. During administration, observe whether there is dirt and excrement in the lower abdomen and anus of the animals, the reactivity when caught, the condition around the eyes, nose and mouth, and the condition of the skin (with or without color change, trauma, tumor, etc.).

[0159] Bronchoalveolar lavage fluid collection

[0160] After the last administration, rats in each group were fasted for 12 hours, and then anesthetized by intraperitoneal injection of 100 mg / L chloral hydrate (3.5 mL / kg). Inject 2 ml of PBS into the lung tissue with a tracheal syringe, gently aspirate it, centrifuge at 2500 r / min for 10 min, aspirate the superna...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of hydroxyprogesterone hexanoate alone or combined with other medicines in preparation of medicines for treating interstitial pneumonia, a method for treating interstitial pneumonia, a corresponding medicine composition and the like. Hydroxyprogesterone hexanoate can relieve lung inflammation and fibrosis symptoms, reduce lung collagen deposition and reduce the levels of various inflammatory factors in alveolar lavage fluid and plasma. When the hydroxyprogesterone hexanoate and the dexamethasone are combined for use, abnormal lipid metabolism and the like caused by independent treatment of the dexamethasone can be improved.

Description

technical field [0001] The present application provides the use of hydroxyprogesterone caproate alone or in combination with other drugs in the preparation of a drug for the treatment of interstitial pneumonia and a method for treating interstitial pneumonia, as well as corresponding pharmaceutical compositions and the like. Background technique [0002] Interstitial lung disease (ILD) refers to a group of heterogeneous diseases characterized by the disorder of cells in the alveolar structure and the matrix in the connective tissue. The main clinical symptoms include dyspnea, hypoxia, and carbon monoxide diffusion. The amount (DLCO) decreased and so on. ILD in a broad sense includes almost all diseases that occur in the pulmonary interstitium with different etiologies, pathogenesis and lesions. At present, there are nearly 200 known causes of ILD, including dust, infection, drugs, inhalation of special gases, etc., but there are still No specific etiology can be identified ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/57A61K31/573A61P11/00
CPCA61K31/57A61K31/573A61P11/00A61K2300/00
Inventor 杜涛胡涛杜新
Owner SHENZHEN EVERGREEN THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com